Overview

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the efficacy and safety of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring T790M mutation
Phase:
Phase 2
Details
Lead Sponsor:
Allist Pharmaceuticals, Inc.